NOVI BIOMARKERI ZA PRIMJENU USMJERENOG LIJEČENJA IMUNOTERAPIJOM U KARCINOMU ENDOMETRIJA
2020
Endometrial cancer (ED) is the most common malignancy of the female reproductive system
and the fourth most common cancer in women in the developed world. In the past decade, the
incidence of ED has increased by 2.4% and mortality by 1.9% per year. This failure in
prevention and treatment rests in part on the fact of a poor understanding of the heterogeneity
and biodiversity of this malignancy. The Cancer Genome Atlas Research Network provides a
new classification of ED which defines four subgroups of cancers based on their genetic
characteristics. The integration of their knowledge into the existing classification seems
necessary to create an optimal diagnostic and prognostic classification. Ultramutated tumors
with a large number of somatic mutations within the polymerase epsilon exonuclease domain
(POLE) and hypermutated tumors with microsatellite instability (MSI) are two subgroups of
the ED with significant expression of PD-1 (programmed death-1) and its ligand PD-L1
(programmed death ligand-1). Pharmacological inhibition of the PD-1 / PD-L1 pathway
enables reactivation of the immune response against the tumor and therefore reduces tumorinduced
immune suppression. This hypothesis has shown successful clinical outcomes in
other types of malignancies such as non-small cell lung cancers, melanoma, kidney, and
bladder cancers. Nivolumab and pembrolizumab, both monoclonal antibodies to the PD-1
lymphocyte receptor, give solid preliminary results in ED immunotherapy and significantly
lower cytotoxicity than standard adjuvant therapy.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI